3.58
-48.49%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Onconetix
From its filings with the US Securities and Exchange Commission
Onconetix is based in Cincinnati, Ohio and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ONCO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $815,371 and a net loss of $14.0m. At that date it held total assets of $24.9m.
ENTADFI program, effective April 30, 2024, with such individuals to continue assisting the Company on an as-needed, consulting basis.
By Realbotix if a Buyer Adverse Recommendation Change (as defined in the Share Exchange Agreement) occurs prior to receipt of Buyer stockholder approval.
By us in connection with entering into a definitive agreement for a Buyer Superior Proposal (as define in the Share Exchange Agreement).
By us if the audited Realbotix financial statements have not been delivered by April 30, 2026.
In the event of a termination of the Share Exchange Agreement by Realbotix for failure to satisfy the Net Cash Condition, if Net Cash at the time of termination would be greater than $5.0 million (assuming the consummation of any Transaction Financing pursuant to Financing Agreements), we are obligated to pay Realbotix’s transaction expenses, with such transaction expenses not to exceed $500,000.
Exchange Agreement agreed to use its commercially reasonable efforts to consummate the Realbotix Transaction.
The aggregate fair value of the common and preferred shares issued as consideration was equal to approximately $65.1 million.
Quoted from its 10-K, filed 13 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Feb 2022
- Employees
- 12
- Website
- bluewatervaccines.com ↗
- Head office
- 201 E. FIFTH STREET, CINCINNATI, OH, 45202
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Ms. Karina FedaszInterim Chief Executive Officer, Interim Chief Financial Officer
- Mr. Andrew OakleyLead Independent Director
- Dr. Thomas MeierIndependent Director
- Mr. Timothy RamdeenIndependent Director$82,669
- Mr. Simon TarshIndependent Director$112,620
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Onconetix Inc's focus on transformational vaccines addresses global health challenges effectively.
- The company's streptococcus pneumonia vaccine candidate targets acute otitis media in children.
- Licensing the norovirus VLP platform from Cincinnati Children’s Hospital enhances vaccine development capabilities.
Weaknesses
- With only 12 employees, Onconetix Inc faces resource constraints in R&D efforts.
- The company's limited workforce may hinder rapid scaling of vaccine production.
- Dependence on external partnerships for vaccine platforms could pose operational risks.
Opportunities
- Expanding the norovirus VLP platform to develop vaccines for Marburg and monkeypox.
- Collaborating with UT Health to advance the Chlamydia vaccine candidate development.
- Growing global demand for universal flu vaccines presents significant market potential.
Threats
- Competition from established biotech firms in the vaccine development sector.
- Regulatory hurdles in obtaining approvals for new vaccine candidates.
- Potential delays in clinical trials for streptococcus pneumonia vaccine candidate.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.